Moderna has scrapped plans to build an mRNA plant in Japan. Otsuka and Lundbeck's proposal for Rexulti as part of a PTSD ...

Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) ...

Pfizer Inc. has completed the previously announced global, ex-China, licensing agreement with 3SBio Inc., which grants Pfizer exclusive rights for the development, manufacturing and commercialization ...

Pfizer is on the brink of a major rebound, transitioning focus to oncology and potential blockbuster drugs after a sharp drop in COVID-related revenues. Pfizer’s stock has plummeted over 50% in the ...

Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

Is Pfizer’s hefty 7% dividend yield safe? Undoubtedly, the name has encountered its fair share of pressures of late. And while the dividend is getting quite stretched, it’s not necessarily at ...

Social media is teeing off on Kansas City Chiefs tight end Travis Kelce after a report revealed how much he gets from Pfizer.

Nippon Steel has completed its acquisition of U.S. Steel, the companies said on Wednesday, more than a year after it was first announced. Soon after Nippon announced its plans to acquire U.S ...

Biopharma deal activity continued its record-breaking pace in 2025, reaching $103.76 billion in total value through the first five months, the highest year-to-date total in BioWorld’s records. That ...

Pfizer CEO discussed due diligence on the 3SBio deal. Otsuka detailed its phase 3 IgAN win. Novartis pressed for speedy ruling Entresto's patent case.

It’s powered by technology that Databricks obtained through its recent acquisition of Neon Inc., a startup with an eponymous serverless PostgreSQL platform.